<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362205">
  <stage>Registered</stage>
  <submitdate>9/03/2012</submitdate>
  <approvaldate>12/03/2012</approvaldate>
  <actrnumber>ACTRN12612000286842</actrnumber>
  <trial_identification>
    <studytitle>VALDA: Volatile Associated Liver Disease Audit</studytitle>
    <scientifictitle>A Prospective Study of The Incidence of Liver Injury Caused by Volatile Anaesthesia In Trauma Patients Undergoing Surgery</scientifictitle>
    <utrn>U1111-1128-9973</utrn>
    <trialacronym>V.A.L.D.A.</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>The incidence of liver disease caused by exposure to volatile anaesthetic agents, in trauma patients.</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Trauma patients admitted and undergoing surgical procedures will have their liver function assessed during admission to ascertain the development of liver disease, potentially resulting from exposure to volatile anaesthetic agents. VALDA occurs typically within days of exposure, and therefore patients will have repeat LFTs taken on admission, and then on days 1, 4, 8 and 12 postoperatively. Those with a characteristic pattern of dysfunction will be followed up with immunoassay, to confirm the development and presence of antibodies typically seen in immune-mediated liver dysfunction (anti-trifluoroactate [TFA] antibodies). Those with abnormal liver function will be followed up by a hepatologist.</interventions>
    <comparator>Trauma patients admitted, but having no surgery, and 
trauma patients undergoing surgery with no volatile exposure (TIVA or regional technique) will have their liver function assessed.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of liver disease attributable to volatile agent exposure, as determined by previously mentioned data. Patients with abnormal over function will be further for concomitant hepatotoxic medications and liver injury. Those suspicious of VALDA will have anti-TFA antibody screening to confirm it.</outcome>
      <timepoint>Development of VALDA within 12 days of exposure.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of liver disease in trauma patients, as determined by abnormal liver function tests.</outcome>
      <timepoint>Within twelve days of surgery.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Trauma patients admitted to Royal Melbourne Hospital.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Brad Hockey</primarysponsorname>
    <primarysponsoraddress>c/- Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Grattan St, Melbourne VIC 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess whether anaesthetic gases in trauma patients may contribute to liver damage.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee (EC00243)</ethicname>
      <ethicaddress>C/- Royal Melbourne Hospital
Grattan St, Melbourne
Victoria 3050</ethicaddress>
      <ethicapprovaldate />
      <hrec>2012.009</hrec>
      <ethicsubmitdate>9/02/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Brad Hockey</name>
      <address>c/- Department of Anaesthesia and Pain Management
3 North, Royal Melbourne Hospital
Grattan St Melbourne
VIC 3050</address>
      <phone>+61393427540</phone>
      <fax>+61393428623</fax>
      <email>brad.hockey@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Brad Hockey</name>
      <address>c/- Department of Anaesthesia and Pain Management
3 North, Royal Melbourne Hospital
Grattan St, Melbourne
VIC 3050</address>
      <phone>+61393427540</phone>
      <fax>+61393428623</fax>
      <email>brad.hockey@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>